EFFICACY OF ARIPIPRAZOLE AND RISPERIDONE IN TREATMENT OF CHILDREN WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER: A DOUBLE-BLIND CLINICAL TRIAL STUDY
Dreakhshanpour, F., Deylamsalehi, A., Moghadda, S., Shahini, N. (2022). EFFICACY OF ARIPIPRAZOLE AND RISPERIDONE IN TREATMENT OF CHILDREN WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER: A DOUBLE-BLIND CLINICAL TRIAL STUDY. EKB Journal Management System, 45(1), 281-288. doi: 10.21608/bfsa.2022.239464
Firoozeh Dreakhshanpour; Anahita Deylamsalehi; Seyed Shahab Jazayeri Moghadda; Najmeh Shahini. "EFFICACY OF ARIPIPRAZOLE AND RISPERIDONE IN TREATMENT OF CHILDREN WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER: A DOUBLE-BLIND CLINICAL TRIAL STUDY". EKB Journal Management System, 45, 1, 2022, 281-288. doi: 10.21608/bfsa.2022.239464
Dreakhshanpour, F., Deylamsalehi, A., Moghadda, S., Shahini, N. (2022). 'EFFICACY OF ARIPIPRAZOLE AND RISPERIDONE IN TREATMENT OF CHILDREN WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER: A DOUBLE-BLIND CLINICAL TRIAL STUDY', EKB Journal Management System, 45(1), pp. 281-288. doi: 10.21608/bfsa.2022.239464
Dreakhshanpour, F., Deylamsalehi, A., Moghadda, S., Shahini, N. EFFICACY OF ARIPIPRAZOLE AND RISPERIDONE IN TREATMENT OF CHILDREN WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER: A DOUBLE-BLIND CLINICAL TRIAL STUDY. EKB Journal Management System, 2022; 45(1): 281-288. doi: 10.21608/bfsa.2022.239464

EFFICACY OF ARIPIPRAZOLE AND RISPERIDONE IN TREATMENT OF CHILDREN WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER: A DOUBLE-BLIND CLINICAL TRIAL STUDY

Bulletin of Pharmaceutical Sciences Assiut University
Article 22, Volume 45, Issue 1, June 2022, Page 281-288  XML PDF (754.33 K)
Document Type: Original Article
DOI: 10.21608/bfsa.2022.239464
View on SCiNiTO View on SCiNiTO
Authors
Firoozeh Dreakhshanpour1; Anahita Deylamsalehi2; Seyed Shahab Jazayeri Moghadda3; Najmeh Shahini email 4
1Associated Professor of Psychiatry, Golestan Research Center of Psychiatry, Golestan University of Medical Sciences, Gorgan, Iran
2MPH Student ,San Jose State University , California,USA
3Internal Medicine, Saint Mary´s Hospital, Waterbury, Connecticut
4Assistant Professor of Psychiatry, Golestan Research Center of Psychiatry, Golestan University of Medical Sciences, Gorgan, Iran
Abstract
Attention-deficit hyperactivity disorder (ADHD) is one of the most common psychiatric disorders in children. Poor academic readiness for school entry, fine motor skills, and social impairment are more common in preschoolers than healthy controls. Since dopaminergic system dysfunction is connected with numerous neuropsychological diseases, including ADHD, antipsychotic drugs are used for the treatment of ADHD. Considering the importance of ADHD treatment in preschoolers and the fact that psychostimulant drugs are less effective in preschoolers and have more adverse effects, this study is conducted to compare the safety and efficacy of risperidone and aripiprazole in the treatment of ADHD. Fifty-five 3-6-year-old children diagnosed with ADHD were randomized to a 12-week trial of treatment with risperidone or aripiprazole1. The assessment was performed by Parent ADHD-RS, Strengths and Difficulties Questionnaire (SDQ), Children's Global Assessment Scale (CGAS) before treatment, and weeks 2, 4, 6, and 12 of treatment. The study showed that the ADHD-RS score of both groups was significantly reduced after starting the treatment. After the 12th week, the score of aripiprazole's group was significantly less than the score of risperidone's group (p-value = 0.019). In addition, the CGAS scores and the total SDQ score improved for both groups without any statistically significant difference between them. Both risperidone and aripiprazole are effective in the treatment of ADHD among preschool-aged children. Both drugs are well-tolerated, significantly reduce the ADHD-RS score and the total SDQ score and improve the CGAS score.
Keywords
Attention-deficit hyperactivity disorder; Aripiprazole; Risperidone; clinical trial
Statistics
Article View: 434
PDF Download: 417